Therapeutic strategies targeting specific miRNAs or transcription factors, such as using miRNA mimics or inhibitors, as well as developing small molecule inhibitors against the NF-κB signaling pathway, could emerge as new approaches for treating gout with concurrent atherosclerosis. This evidence concerns the gene NFKB1 and atherosclerosis.